Shots:
- Health Canada has accepted NDS of CHIKV VLP for active immunization against CHIKV disease in individuals (≥12yrs.); decision is anticipated in H1’26
- NDS was based on 2 P-III trials (n>3,500) that met their 1EP, with 97.8% of subjects aged 12–64yrs. & 87.3% aged >65yrs. developing neutralizing antibodies by day 21 post vaccination; seroresponse rates (2EP) were 46.6% (day 8) & 96.8% (day 15) for ages 12–64, & 82.3% (day 15) for those >65yrs. after vaccination
- CHIKV VLP is a single dose, prefilled adjuvanted VLP recombinant protein vaccine, which received the US FDA & EC approval in Feb 2025 & May 2025, respectively under the brand name Vimkunya
Ref: Globenewswire | Image: Bavarian Nordic| Press Release
Related News:- Bavarian Nordic Reports the MHRA’s Approval of Vimkunya to Prevent Chikungunya
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
